Compare PROV & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | IMMX |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.1M | 82.6M |
| IPO Year | 1996 | 2021 |
| Metric | PROV | IMMX |
|---|---|---|
| Price | $15.38 | $5.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.25 | $8.00 |
| AVG Volume (30 Days) | 5.9K | ★ 613.1K |
| Earning Date | 10-28-2025 | 11-07-2025 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $39,823,000.00 | N/A |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $12.98 | $1.34 |
| 52 Week High | $16.70 | $5.05 |
| Indicator | PROV | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 74.11 |
| Support Level | $15.01 | $3.78 |
| Resistance Level | $15.65 | $4.48 |
| Average True Range (ATR) | 0.41 | 0.44 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 34.07 | 96.86 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.